Abstract: A method of providing information related to a charge status of an electric vehicle includes monitoring, with a system controller in communication with an electrical system within the vehicle, information related to a charge status of the vehicle, and, displaying, with the system controller, for a person in proximity of the vehicle, information related to a charge status of the vehicle.

Abstract: A levodopa derivative including a compound or pharmaceutically acceptable salt, hydrate, and/or solvate thereof, wherein the compound includes substituents which, in aggregate, contain at least 6 carbon atoms which are only bonded to either other carbon atoms or to hydrogen atoms. The levodopa derivative may be formulated as a composition including one or more pharmaceutically acceptable carriers or excipients. The levodopa derivative may be part of a pharmaceutical composition including micro or nano particles in which the levodopa derivative is encapsulated in the pharmaceutically acceptable polymer. The levodopa derivative can be used to treat Parkinson's disease by administering to a mammal an amount sufficient to treat Parkinson's disease.

Abstract: A system for notifying an authority about road conditions for a vehicle may include a plurality of vehicle sensors, a vehicle communication system, and a controller in electrical communication with the plurality of vehicle sensors and the vehicle communication system. The controller is programmed to identify a measurement trigger. The controller is further programmed to perform a measurement of an environment surrounding the vehicle using the plurality of vehicle sensors in response to identifying the measurement trigger. The controller is further programmed to determine a measurement classification based at least in part on the measurement. The controller is further programmed to transmit the measurement and the measurement classification to a remote server system using the vehicle communication system.

Abstract: A system for providing an alert to an occupant within a vehicle includes a system controller in communication with a plurality of onboard sensors, other vehicles and infrastructure systems, an augmented reality head up display system and a full windshield display system, each adapted to project images onto an inner surface of a windshield of the vehicle, the system controller adapted to detect at least one approaching vehicle, calculate a distance from the intersection, speed and trajectory of the at least one approaching vehicle, determine if the at least one approaching vehicle poses a threat and classify the at least one approaching vehicle as a threat vehicle, and provide a warning message and augmentation graphics by projecting the warning message and augmentation graphics onto the inner surface of the windshield with at least one of the AR-HUD system and the full windshield display system.

Abstract: The invention relates to stable formulations comprising antibodies or antigen binding fragments thereof that bind to cytotoxic T lymphocyte associated antigen 4 (CTLA4), optionally further containing an anti-human programmed death receptor 1 (PD-1) antibody or antigen binding fragment thereof. Also provided are methods of treating various cancers and chronic infections with the formulations of the invention.

Abstract: A system for providing information related to a charge status of an electric vehicle when the electric vehicle is connected to a charging station includes a system controller in communication with an electrical system within the electric vehicle and adapted to monitor information related to a charge status of the electric vehicle, and provide notification, to a third-party, of the charge status of the electric vehicle.

Abstract: A method of providing information related to a charge status of an electric vehicle includes monitoring, with a system controller in communication with an electrical system within the vehicle, information related to a charge status of the vehicle, and, displaying, with the system controller, for a person in proximity of the vehicle, information related to a charge status of the vehicle.

Abstract: A method of providing information related to a charge status of an electric vehicle when the electric vehicle is being used as a battery pack includes detecting, with a system controller in communication with an electrical system within the vehicle, when the electric vehicle is being used to provide power to an external electrical device, and when the electric vehicle is being used to provide power to an external electrical device, monitoring, with the system controller in communication with the electrical system within the electric vehicle, information related to a charge status of the electric vehicle, and providing notification, to a person in proximity to the electric vehicle, with the system controller, the charge status of the electric vehicle.

Abstract: A system for imaging through an obscurant, includes a spatial light modulator (SLM) or a deformable mirror array (DMA) configured to modulate light, one or more sensors configured to capture an image, a processor, and a memory. The memory includes instructions stored thereon, which when executed by the processor cause the system to: incoherently illuminate a target by a light, the obscurant scatters the light creating an optical aberration; modulating the scattered light by the SLM or DMA; capture an image by the one or more sensors of the target as illuminated by the modulated light; generate a simulated image by a differential model; compare the captured image with the simulated image; estimate the target, the aberration, and a phase delay based on back-propagation of the comparison; and correct for the aberration based on at least one of the estimated target, the aberration, or the phase delay.

Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti- PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.

Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.

Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.

Abstract: The invention relates to stable formulations comprising antibodies or antigen binding fragments thereof that bind to cytotoxic T lymphocyte associated antigen 4 (CTLA4), optionally further containing an anti-human programmed death receptor 1 (PD-1) antibody or antigen binding fragment thereof. Also provided are methods of treating various cancers and chronic infections with the formulations of the invention.

Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.

Abstract: The present invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. The present invention further provides methods for treating various cancers and chronic infections with stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof.

Abstract: The present invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. The present invention further provides methods for treating various cancers and chronic infections with stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof.

Abstract: A diagnostic kit for measuring a characteristic of a fluid sample includes a test strip (e.g., a disposable blood glucose test strip) and device (e.g., a hand-held meter) for measuring a property (e.g., an optical or electrochemical property) of the test strip. The device also calculates, based on the measured property of the test strip, a characteristic (e.g., blood glucose concentration or INR) of a fluid sample applied to the test strip. Stored in a memory of the device are test strip calibration codes that represent geometric regions (e.g., polygonal or hexagonal geometric regions) of a multi-dimensional calibration parameter space. The test strip calibration codes and geometric regions are distributed across the multi-dimensional calibration parameter space such that a quantization error of assigning one of test strip calibration codes to the test strip is optimally reduced.

Abstract: A diagnostic kit for measuring a characteristic of a fluid sample includes a test strip (e.g., a disposable blood glucose test strip) and device (e.g., a hand-held meter) for measuring a property (e.g., an optical or electrochemical property) of the test strip. The device also calculates, based on the measured property of the test strip, a characteristic (e.g., blood glucose concentration or INR) of a fluid sample applied to the test strip. Stored in a memory of the device are test strip calibration codes that represent geometric regions (e.g., polygonal or hexagonal geometric regions) of a multi-dimensional calibration parameter space. The test strip calibration codes and geometric regions are distributed across the multi-dimensional calibration parameter space such that a quantization error of assigning one of test strip calibration codes to the test strip is optimally reduced.